---
id: 2025-12-25_003
title: "Connect1d as core Suite 5 use case: decentralized T1D trials"
type: text
status: new
priority: high
created: 2025-12-25T00:30:00Z
links:
  documents: ["suites/suite_5_trial_innovation.md", "suites/suite_4_data_platform.md"]
  objectives: [2, 5, 7]
  suites: [4, 5]
tags: [Connect1d, decentralized-trials, diabetes, ADI, wearables, TRE, Peter-Senior]
---

# Idea

Connect1d Canada is being taken over by Peter Senior and the Alberta Diabetes Institute (ADI). This platform is focused on decentralized clinical trials for Type 1 Diabetes and should be well represented as the core use case for Suite 5 (Trial Innovation Tools & Wearables).

The platform could use the TRE infrastructure created with AWS for deployment and implementation, as well as integration with the Alberta Health Services data environment (likely Snowflake-based). Connect1d is a good example of an integrated project requiring a "data integration" layer that the Suite 4 TRE and data platform can provide.

---

## Research Summary: Connect1d Canada

### What is Connect1d?

**Connect1d Canada** is a patient-engagement platform and digital registry connecting people living with Type 1 Diabetes (T1D) with researchers to accelerate clinical trials, improve care, treatments, and quality of life.

**Key Facts:**
- Founded by Dr. Joe Cafazzo (UHN), Dr. Bruce Perkins (Sinai), and **Dr. Peter Senior (ADI)**
- Launched 2021, funded by JDRF Canada and CIHR/Diabetes Action Canada
- Platform developed at Centre for Global eHealth Innovation, UHN Toronto
- Transition to ADI leadership under Peter Senior

### Mission and Purpose

> "Connect1d Canada empowers people living with T1D to advance research, policy and clinical care."

**Problem Solved:**
- Canadian researchers struggle to recruit for clinical trials
- No systematic process to identify/engage T1D population nationally
- Studies unable to reach recruitment targets for years
- T1D community unaware of research opportunities

**Solution:**
- Digital-first registry connecting patients with researchers
- Patient-reported data collection with user control
- Study matching based on interests and eligibility
- Accelerated recruitment with diverse participant pool

### Current Capabilities

**For Participants:**
- Access to active research studies
- Meaningful participation in research design
- Study outcome updates
- Preference-controlled data sharing

**For Researchers:**
- Streamlined recruitment
- Access to diverse Canadian T1D population
- Patient-centered research facilitation
- Competitive advantage for patient engagement

**Active Studies Include:**
- SGLT2 inhibitor preference study
- Fasted exercise training (at ADI)
- Virtual care for gestational diabetes
- TrialNet Pathway to Prevention screening

### Partnerships

- CIHR / Diabetes Action Canada (SPOR)
- JDRF Canada / Breakthrough T1D
- University Health Network (Toronto)
- University of Toronto
- T1D Exchange (international partner)

---

## Integration with CFI CTAP

### Suite 5 Alignment

Connect1d directly addresses Suite 5's core objectives:

| Suite 5 Capability | Connect1d Contribution |
|--------------------|------------------------|
| **eConsent** | Digital consent already integrated |
| **Participant recruitment** | AI-assisted matching to studies |
| **Decentralized trials** | Pan-Canadian reach, remote participation |
| **Wearable integration** | CGM data streams, diabetes devices |
| **Equity focus** | Reaching rural/remote T1D populations |
| **Patient engagement portal** | Existing portal infrastructure |

### Suite 4 Data Platform Integration

Connect1d represents an ideal use case for the TRE "data integration layer":

```
┌─────────────────────────────────────────────────────────────────┐
│                    CONNECT1D DATA FLOWS                          │
├─────────────────────────────────────────────────────────────────┤
│                                                                  │
│  ┌──────────────┐     ┌──────────────┐     ┌──────────────┐     │
│  │ Connect1d    │     │ Wearables    │     │ Connect Care │     │
│  │ Platform     │     │ (CGM, etc.)  │     │ (AHS)        │     │
│  │ User Data    │     │ Device Data  │     │ EHR Data     │     │
│  └──────┬───────┘     └──────┬───────┘     └──────┬───────┘     │
│         │                    │                    │              │
│         ▼                    ▼                    ▼              │
│  ┌─────────────────────────────────────────────────────────┐    │
│  │              SUITE 4: TRE DATA INTEGRATION               │    │
│  │  ┌────────────────────────────────────────────────────┐ │    │
│  │  │ Zone 2: Controlled Processing                      │ │    │
│  │  │ - Consent verification                             │ │    │
│  │  │ - De-identification                                │ │    │
│  │  │ - OMOP transformation                              │ │    │
│  │  │ - Snowflake integration (AHS)                      │ │    │
│  │  └────────────────────────────────────────────────────┘ │    │
│  │  ┌────────────────────────────────────────────────────┐ │    │
│  │  │ Zone 3: Research Environment                       │ │    │
│  │  │ - Integrated T1D research database                 │ │    │
│  │  │ - CGM + EHR + patient-reported outcomes            │ │    │
│  │  │ - Trial-ready cohorts                              │ │    │
│  │  └────────────────────────────────────────────────────┘ │    │
│  └─────────────────────────────────────────────────────────┘    │
│         │                                                        │
│         ▼                                                        │
│  ┌──────────────────────────────────────────────────────────┐   │
│  │ RESEARCH OUTPUTS                                          │   │
│  │ - T1D trial recruitment                                   │   │
│  │ - Longitudinal outcomes research                          │   │
│  │ - AI/ML biomarker development                             │   │
│  │ - Real-world evidence generation                          │   │
│  └──────────────────────────────────────────────────────────┘   │
└─────────────────────────────────────────────────────────────────┘
```

### AHS Snowflake Integration

The idea notes that AHS data environment is "likely Snowflake-based" with case-by-case data sharing. The TRE can serve as:

1. **Intermediary Layer**: Receive AHS data via approved agreements
2. **Linking Engine**: Connect Connect1d participants to their EHR data
3. **Privacy Layer**: De-identification before research use
4. **Federation Point**: Enable queries without raw data movement

### AWS TRE Deployment

Connect1d could leverage the AWS TRE infrastructure:

| TRE Capability | Connect1d Application |
|----------------|----------------------|
| **AWS Calgary region** | Canadian data residency |
| **Zone 3 compute** | Scalable analysis of CGM data |
| **OMOP CDM** | Standardized diabetes phenotypes |
| **REDCap integration** | EDC for T1D trials |
| **CRAIDL agents** | Protocol design for diabetes trials |

---

## Strategic Value

### For CFI Application

1. **Concrete Use Case**: Demonstrates Suite 4+5 integration with real platform
2. **National Reach**: Pan-Canadian engagement extends beyond Alberta
3. **Patient-Centered**: Aligns with CFI emphasis on patient partnership
4. **Existing Infrastructure**: Leverages UHN platform development
5. **ADI Leadership**: Peter Senior brings credibility and continuity

### For Alberta Diabetes Institute

1. **Enhanced Capability**: TRE provides data integration layer
2. **Connect Care Integration**: Access to provincial EHR data
3. **Wearable Data Management**: Infrastructure for CGM and device data
4. **Research Acceleration**: Faster trial recruitment and execution

### For CTAP Flagships

Connect1d could support multiple flagship programs:

| Flagship | Connect1d Contribution |
|----------|------------------------|
| **Cardio-Renal-Metabolic** | T1D patients with kidney/cardiac complications |
| **Precision Population Health** | Diabetes as high-prevalence condition |
| **Decentralized Trials Model** | Proof-of-concept for patient-centric design |

---

## Implementation Considerations

### Technical Integration

1. **Platform Migration/Extension**
   - Connect1d currently hosted at UHN
   - Determine hosting model (stay at UHN vs. migrate to ADI/AWS)
   - API integration with TRE regardless of hosting

2. **Data Governance**
   - Patient consent for Connect Care linkage
   - OCAP considerations if Indigenous participants
   - T1D Exchange international data sharing

3. **Wearable Data Streams**
   - CGM data ingestion pipeline
   - Device certification for research use
   - Real-time vs. batch processing

### Partnership Structure

- **Peter Senior (ADI)**: Scientific lead, clinical integration
- **Joe Cafazzo (UHN)**: Platform technology
- **Diabetes Action Canada**: National SPOR network
- **JDRF/Breakthrough T1D**: Funding, patient community

---

## Recommended Actions

### For RTA Development

1. **Feature Connect1d Prominently** in Suite 5 description
2. **Describe Data Integration Architecture** showing Connect1d → TRE → Connect Care flow
3. **Include Peter Senior** as key personnel for Suite 5 or cross-cutting
4. **Letter of Support** from Diabetes Action Canada / Connect1d leadership

### For Suite 5 Document Updates

1. Add Connect1d as explicit "Decentralized Trials Exemplar"
2. Add CGM/diabetes wearables to device inventory
3. Reference existing Connect1d recruitment success
4. Describe patient registry + TRE integration model

### For Suite 4 Document Updates

1. Add Connect1d as use case for "data integration layer"
2. Describe AHS Snowflake → TRE → Connect1d data flow
3. Reference diabetes-specific OMOP phenotypes

---

## Dr. Peter Senior: Key Personnel

**Current Roles:**
- Director, Alberta Diabetes Institute
- Charles A Allard Chair in Diabetes Research
- Professor of Medicine, University of Alberta
- Medical Director, Clinical Islet Transplant Program
- Scientific Co-Lead, Connect1d Canada
- Past Chair, Diabetes Canada Board (2021-2024)

**Expertise:**
- Type 1 diabetes, hypoglycemia, islet transplantation
- 300+ islet transplant recipients cared for
- Developer of BETA-2 Score for islet graft function
- Creator of "How 2 Type 1" self-management program

**Strategic Value:**
- Co-founder of Connect1d (not just new leadership)
- National profile through Diabetes Canada
- Clinical and research credibility
- ADI director = institutional alignment

---

## Sources

- [Connect1d Canada](https://connect1d.ca/)
- [Diabetes Action Canada - Connect1d](https://diabetesaction.ca/connect1d/)
- [Connect1d T1D Exchange Partnership](https://diabetesaction.ca/connect1d-canada-partners-with-the-t1d-exchange/)
- [BBDC News - Connect1d Launch](https://bbdc.org/news/connect1d-canada-aims-to-connect-t1d-researchers-with-interested-study-participants/)
- [Peter Senior - UAlberta Directory](https://apps.ualberta.ca/directory/person/psenior)
- [Peter Senior - ResearchGate Profile](https://www.researchgate.net/profile/Peter-Senior)
- [ADI Clinical Research Studies](https://www.ualberta.ca/en/alberta-diabetes/clinical-research/clinical-research-studies/index.html)
- [Edmonton Protocol 25 Years](https://www.ualberta.ca/en/department-of-medicine/news-events/department-news/2025/06/peter-senior-edmonton-protocol-diabetes-treatment-celebrates-25-years.html)
